Smith & Nephew Plc (SNN)

$24.61

+0.16

(+0.65%)▲

Market is closed - opens 7 PM, 30 Apr 2024

Insights on Smith & Nephew Plc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 1.36B → 2.79B (in $), with an average increase of 26.1% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 172.0M → 90.27M (in $), with an average decrease of 47.5% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 40.4% return, outperforming this stock by 65.6%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 67.8% return, outperforming this stock by 111.2%

Performance

  • $24.47
    $24.74
    $24.61
    downward going graph

    0.59%

    Downside

    Day's Volatility :1.11%

    Upside

    0.53%

    downward going graph
  • $21.13
    $32.09
    $24.61
    downward going graph

    14.14%

    Downside

    52 Weeks Volatility :34.15%

    Upside

    23.31%

    downward going graph

Returns

PeriodSmith & Nephew PlcSector (Health Care)Index (Russel 2000)
3 Months
-12.05%
-0.4%
0.0%
6 Months
11.19%
13.0%
0.0%
1 Year
-25.16%
4.8%
0.0%
3 Years
-43.36%
15.4%
-21.9%

Highlights

Market Capitalization
10.7B
Book Value
$5.98
Dividend Share
0.375
Dividend Yield
3.05%
Earnings Per Share (EPS)
0.6
PE Ratio
40.95
PEG Ratio
0.45
Wall Street Target Price
31.5
Profit Margin
4.74%
Operating Margin TTM
14.46%
Return On Assets TTM
4.27%
Return On Equity TTM
5.02%
Revenue TTM
5.5B
Revenue Per Share TTM
2.55
Quarterly Revenue Growth YOY
7.6%
Gross Profit TTM
3.7B
EBITDA
1.1B
Diluted Eps TTM
0.6
Quarterly Earnings Growth YOY
0.98
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    63%Buy
    27%Hold
    9%Sell
Based on 22 Wall street analysts offering stock ratings for Smith & Nephew Plc(by analysts ranked 0 to 5 stars)
Based on 22 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
13
14
Hold
6
6
5
Sell
2
2
3

Analyst Forecast

What analysts predicted

Upside of 28.0%

Current $24.61
Target $31.50

Company Financials

FY18Y/Y Change
Revenue
4.9B
↑ 2.92%
Net Income
663.0M
↓ 13.56%
Net Profit Margin
13.52%
↓ 2.58%
FY19Y/Y Change
Revenue
5.1B
↑ 4.77%
Net Income
600.0M
↓ 9.5%
Net Profit Margin
11.68%
↓ 1.84%
FY20Y/Y Change
Revenue
4.6B
↓ 11.25%
Net Income
448.0M
↓ 25.33%
Net Profit Margin
9.82%
↓ 1.86%
FY21Y/Y Change
Revenue
5.2B
↑ 14.3%
Net Income
524.0M
↑ 16.96%
Net Profit Margin
10.05%
↑ 0.23%
FY22Y/Y Change
Revenue
5.2B
↑ 0.06%
Net Income
223.0M
↓ 57.44%
Net Profit Margin
4.28%
↓ 5.77%
FY23Y/Y Change
Revenue
5.5B
↑ 6.4%
Net Income
263.0M
↑ 17.94%
Net Profit Margin
4.74%
↑ 0.46%
Q2 FY22Q/Q Change
Revenue
2.6B
↑ 100.0%
Net Income
177.0M
↑ 100.0%
Net Profit Margin
6.81%
↑ 0.0%
Q3 FY22Q/Q Change
Revenue
1.3B
↓ 49.71%
Net Income
23.0M
↓ 87.01%
Net Profit Margin
1.76%
↓ 5.05%
Q4 FY22Q/Q Change
Revenue
2.7B
↑ 109.79%
Net Income
48.3M
↑ 109.79%
Net Profit Margin
1.76%
↑ 0.0%
Q1 FY23Q/Q Change
Revenue
1.4B
↓ 50.16%
Net Income
86.0M
↑ 78.23%
Net Profit Margin
6.29%
↑ 4.53%
Q2 FY23Q/Q Change
Revenue
2.7B
↑ 100.0%
Net Income
172.0M
↑ 100.0%
Net Profit Margin
6.29%
↑ 0.0%
Q4 FY23Q/Q Change
Revenue
2.8B
↑ 2.14%
Net Income
90.3M
↓ 47.51%
Net Profit Margin
3.23%
↓ 3.06%
FY18Y/Y Change
Total Assets
8.1B
↑ 2.45%
Total Liabilities
3.2B
↓ 1.15%
FY19Y/Y Change
Total Assets
9.3B
↑ 15.39%
Total Liabilities
4.2B
↑ 30.55%
FY20Y/Y Change
Total Assets
11.0B
↑ 18.42%
Total Liabilities
5.7B
↑ 37.88%
FY21Y/Y Change
Total Assets
10.9B
↓ 0.84%
Total Liabilities
5.4B
↓ 6.65%
FY22Y/Y Change
Total Assets
10.0B
↓ 8.74%
Total Liabilities
4.7B
↓ 12.05%
FY23Y/Y Change
Total Assets
10.0B
↑ 0.21%
Total Liabilities
4.8B
↑ 1.34%
Q2 FY22Q/Q Change
Total Assets
10.1B
↓ 7.46%
Total Liabilities
4.7B
↑ 0.0%
Q3 FY22Q/Q Change
Total Assets
10.1B
↑ 0.0%
Total Liabilities
4.7B
↓ 0.06%
Q4 FY22Q/Q Change
Total Assets
10.0B
↓ 1.38%
Total Liabilities
4.7B
↑ 0.0%
Q1 FY23Q/Q Change
Total Assets
10.0B
↑ 0.0%
Total Liabilities
4.6B
↓ 2.04%
Q2 FY23Q/Q Change
Total Assets
9.8B
↓ 1.22%
Total Liabilities
4.6B
↑ 0.0%
Q4 FY23Q/Q Change
Total Assets
10.0B
↑ 1.45%
Total Liabilities
4.8B
↑ 3.45%
FY18Y/Y Change
Operating Cash Flow
931.0M
↓ 14.59%
Investing Cash Flow
-378.0M
↓ 30.39%
Financing Cash Flow
-371.0M
↓ 14.52%
FY19Y/Y Change
Operating Cash Flow
1.2B
↑ 25.46%
Investing Cash Flow
-1.3B
↑ 230.95%
Financing Cash Flow
7.0M
↓ 101.89%
FY20Y/Y Change
Operating Cash Flow
935.0M
↓ 19.95%
Investing Cash Flow
-606.0M
↓ 51.56%
Financing Cash Flow
1.2B
↑ 16528.57%
FY21Y/Y Change
Operating Cash Flow
877.0M
↓ 6.2%
Investing Cash Flow
-691.0M
↑ 14.03%
Financing Cash Flow
-645.0M
↓ 155.41%
FY22Y/Y Change
Operating Cash Flow
468.0M
↓ 46.64%
Investing Cash Flow
-472.0M
↓ 31.69%
Financing Cash Flow
-926.0M
↑ 43.57%
Q2 FY22Q/Q Change
Operating Cash Flow
209.0M
↑ 101.93%
Investing Cash Flow
-134.0M
↑ 0.0%
Financing Cash Flow
-704.0M
↑ 100.0%
Q3 FY22Q/Q Change
Operating Cash Flow
130.5M
↓ 37.56%
Investing Cash Flow
-102.0M
↓ 23.88%
Financing Cash Flow
-111.0M
↓ 84.23%
Q4 FY22Q/Q Change
Operating Cash Flow
130.5M
↑ 0.0%
Investing Cash Flow
-472.0M
↑ 362.75%
Financing Cash Flow
-111.0M
↑ 0.0%
Q1 FY23Q/Q Change
Operating Cash Flow
56.5M
↓ 56.7%
Investing Cash Flow
-91.0M
↓ 80.72%
Financing Cash Flow
-43.0M
↓ 61.26%
Q2 FY23Q/Q Change
Operating Cash Flow
56.5M
↑ 0.0%
Investing Cash Flow
-182.0M
↑ 100.0%
Financing Cash Flow
-43.0M
↑ 0.0%

Technicals Summary

Sell

Neutral

Buy

Smith & Nephew Plc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Smith & Nephew Plc
Smith & Nephew Plc
-0.37%
11.19%
-25.16%
-43.36%
-37.39%
Stryker Corporation
Stryker Corporation
-5.37%
27.81%
11.91%
27.79%
77.66%
Boston Scientific Corp.
Boston Scientific Corp.
7.44%
46.19%
38.58%
67.82%
97.12%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-8.3%
38.6%
-1.28%
-10.21%
48.74%
Abbott Laboratories
Abbott Laboratories
-4.07%
15.62%
-3.22%
-10.45%
35.16%
Medtronic Plc
Medtronic Plc
-8.37%
13.96%
-12.06%
-39.09%
-10.21%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Smith & Nephew Plc
Smith & Nephew Plc
40.95
40.95
0.45
0.0
0.05
0.04
0.03
5.98
Stryker Corporation
Stryker Corporation
40.83
40.83
2.92
11.85
0.18
0.07
0.01
48.92
Boston Scientific Corp.
Boston Scientific Corp.
68.14
68.14
1.8
2.25
0.09
0.04
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
38.53
37.58
5.19
2.75
0.21
0.12
NA
11.83
Abbott Laboratories
Abbott Laboratories
33.3
33.3
5.99
4.6
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
25.52
25.52
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Smith & Nephew Plc
Smith & Nephew Plc
Buy
$10.7B
-37.39%
40.95
4.74%
Stryker Corporation
Stryker Corporation
Buy
$128.2B
77.66%
40.83
15.44%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$107.2B
97.12%
68.14
11.18%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$53.3B
48.74%
38.53
23.01%
Abbott Laboratories
Abbott Laboratories
Buy
$185.5B
35.16%
33.3
13.96%
Medtronic Plc
Medtronic Plc
Buy
$106.7B
-10.21%
25.52
13.0%

Institutional Holdings

  • Fiduciary Management, Inc. of Milwaukee

    1.11%

  • Scharf Investments

    0.68%

  • Goldman Sachs Group Inc

    0.61%

  • TPG GP A, LLC

    0.53%

  • Morgan Stanley - Brokerage Accounts

    0.45%

  • Barrow Hanley Mewhinney & Strauss LLC

    0.39%

Corporate Announcements

  • Smith & Nephew Plc Dividends September,2024

    In the quarter ending September,2024. Smith & Nephew Plc has declared dividend of $0.46

    Read More

Company Information

Smith & Nephew plc, also known as Smith+Nephew, is a British multinational medical equipment manufacturing company headquartered in Watford, England.

Organization
Smith & Nephew Plc
Employees
18452
CEO
Dr. Deepak S. Nath Ph.D.
Industry
Health Technology

Discover More

FAQs